首页|Karolinska Institute Reports Findings in Artificial Intelligence (Effectiveness and Cost-effectiveness of Artificial Intelligence-assisted Pathology for Prostat e Cancer Diagnosis in Sweden: A Microsimulation Study)
Karolinska Institute Reports Findings in Artificial Intelligence (Effectiveness and Cost-effectiveness of Artificial Intelligence-assisted Pathology for Prostat e Cancer Diagnosis in Sweden: A Microsimulation Study)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Artificial Intelligenc e is the subject of a report. According to news reporting originating from Stock holm, Sweden, by NewsRx correspondents, research stated, “Image-based artificial intelligence (AI) methods have shown high accuracy in prostate cancer (PCa) det ection. Their impact on patient outcomes and cost effectiveness in comparison to human pathologists remains unknown.” Our news editors obtained a quote from the research from Karolinska Institute, “ Our aim was to evaluate the effectiveness and cost-effectiveness of AI-assisted pathology for PCa diagnosis in Sweden. We modeled quadrennial prostate-specific antigen (PSA) screening for men between the ages of 50 and 74 yr over a lifetime horizon using a health care perspective. Men with PSA 3 ng/ml were referred for standard biopsy (SBx), for which cores were either examined via AI followed by a pathologist for AI-labeled positive cores, or a pathologist alone. The AI perf ormance characteristics were estimated using an internal STHLM3 validation data set. Outcome measures included the number of tests, PCa incidence and mortality, overdiagnosis, quality-adjusted life years (QALYs), and the potential reduction in pathologist-evaluated biopsy cores if AI were used. Cost-effectiveness was a ssessed using the incremental cost-effectiveness ratio. In comparison to a patho logist alone, the AI-assisted workflow increased the number of PSA tests, SBx pr ocedures, and PCa deaths by 0.03%, and slightly reduced PCa inciden ce and overdiagnosis. AI would reduce the proportion of biopsy cores evaluated b y a pathologist by 80%. At a cost of €0 per case, the AI-assisted workflow would cost less and result in <0.001% lower QALYs in comparison to a pathologist alone. The results were sensitive to the AI cost. According to our model, AI-assisted pathology would significantly d ecrease the workload of pathologists, would not affect patient quality of life, and would yield cost savings in Sweden when compared to a human pathologist alon e. We compared outcomes for prostate cancer patients and relevant costs for two methods of assessing prostate biopsies in Sweden: (1) artificial intelligence (A I) technology and review of positive biopsies by a human pathologist; and (2) a human pathologist alone for all biopsies. We found that addition of AI would red uce the pathology workload and save money, and would not affect patient outcomes when compared to a human pathologist alone.”
StockholmSwedenEuropeArtificial In telligenceCancerDiagnostics and ScreeningEmerging TechnologiesHealth and MedicineMachine LearningOncologyPathologyProstate CancerProstatic Neo plasms
NETL
NSTL
